CordenPharma is undertaking a major expansion of its manufacturing capabilities to meet the global need for GLP-1 agonist-containing therapies, the Basel-based firm said on 16 July. In all, the contract manufacturing and development organization plans to spend approximately €900m (about $981.4m) over the next three years to expand a manufacturing site in Colorado and build a new site in Europe as well.
In an interview, CEO Michael Quirmbach said he could not divulge which companies CordenPharma is or will be providing GLP-1 peptides for, but the company said it has inked multiple, long-term
Key Takeaways
-
CordenPharma will invest about €900m over the next three years to increase its capacity to supply GLP-1 peptides to customers who market type 2 diabetes and obesity medications.
-
The Switzerland-based CDMO has signed contracts worth more than €3bn to provide peptides, but is not disclosing who its customers are
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
